Eisana Corp
Eisana Corp is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Eisana Corp.
Eisana Corp is a company.
Key people at Eisana Corp.
Key people at Eisana Corp.
Eisana Corp (also known as Eisana Health) is an early-stage medical device company developing oncology solutions to prevent and treat side effects of cancer treatment, such as chemotherapy-induced peripheral neuropathy (CIPN) and hair loss.[1][2][3][4][5] Founded in 2020 and based in The Woodlands/Spring, Texas, it serves cancer patients by providing electrical stimulation devices that improve quality of life and aim to reduce healthcare costs associated with treatment side effects.[1][3][4] With 4 employees and $660,000 in funding raised, the company focuses on a platform for multiple products in this niche, showing early traction through SBIR involvement and a dedicated leadership team.[1][2]
Eisana Corp was founded in 2020 in The Woodlands, Texas, by Dr. Carole Spangler Vaughn, who serves as CEO, founder, inventor, and director.[1][4][5] Vaughn, holding a Ph.D. in Biophysics from Johns Hopkins University and an MBA from the University of Washington, brings over 25 years of experience in biopharma, business development, and medical ventures, including roles at Bristol-Myers Squibb, Dendreon Corporation, and as owner of MediVet Hawaii.[4] The idea emerged from her expertise in addressing cancer treatment side effects, particularly CIPN, as highlighted in CEO discussions on the company's site.[5] Early traction includes securing $660K in funding and building a small team, with pivotal hires like VP of Product Development Jessica Urban (25+ years in medical devices) and experienced executives in product management and finance.[1][4]
Eisana rides the wave of precision oncology and medtech innovation, where advances in electrical stimulation (e.g., neuromodulation) address unmet needs in cancer supportive care amid rising chemotherapy use.[1][5] Timing aligns with growing CIPN prevalence—affects up to 60% of patients—and demand for non-pharmacological solutions, fueled by post-pandemic healthcare cost pressures and aging populations.[1][3] Market forces like SBIR funding and regulatory tailwinds for devices favor nimble startups, positioning Eisana to influence the $10B+ oncology supportive care ecosystem by pioneering accessible, patient-centric tech that complements immuno-oncologies.[2][4]
Eisana's path forward hinges on clinical validation, FDA clearance for lead devices, and scaling its platform amid oncology medtech funding resurgence.[1][4] Trends like AI-enhanced neuromodulation and personalized cancer care will amplify its momentum, potentially expanding to more side effects or global markets. As it grows from $660K funding, expect partnerships with big pharma (leveraging Vaughn's network) to evolve its influence, transforming patient post-treatment experiences from survival to thriving—echoing its core mission since 2020.[1][4][5]
